Questions that our clients ask
- How restrictive will the payer prior authorization be for our product?
- What is our value-based price?
- How will access change for the follow-on indication?
- What will payer management look like in disease state X in the next five years?
- What are the specific access hurdles the practice is experiencing with our product
Specialist therapeutic areas
Oncology, MS, Respiratory Immunology (RA/PsA/CD/UC), Orphan Disease, Haemophilia, Cardiovascular, etc.
Specialized markets
The CBP difference
- We have vast experience supporting the P&MA launch strategy of high-profile brands and can help clients solve highly nuanced problems (i.e. HUB financial assistance program, HRU model.)
- We have extensive experience with high profile dynamics such as: gene therapy, alternative payment models, NGS testing, portfolio contracting, etc.
